Antidotes to vesicant chemotherapy extravasations

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Pharmacologic Extravasation Antidotes. The foregoing sections have reviewed the experimental studies and clinical anecdotes describing potential pharmacologic antidotes to extravasations of vesicant anticancer agents. Numerous prior reviews have also suggested specific antidotes64,176-179 or very conservative, non-pharmacologic approaches.57,180 Many antidotal approaches to extravasation have not been experimentally validated and thus, few 'antidotes' share a rationale which is founded on positive experimental and clinical studies. However, using this criteria, a few active antidotes can be distilled from the literature. These are outlined in Table 6. These antidotes include isotonic ( 1 6 M) sodium thiosulfate for mechlorethamine (and optionally for cisplatin), hyaluronidase for the vinca alkaloids (and optionally for epipodophyllotoxins such as etoposide), and cooling with very topical DMSO and low dose hydrocortisone for the anthracyclines.181 For the alkylating agent mitomycin C, topical DMSO has been effective experimentally but has not yet received clinical validation, at least in published studies. Nonetheless, the severity of mitomycin C ulcerations21 and the documented safety of topical DMSO in the small series of doxorubicin extravasation patients105 argues for its use when mitomycin extravasates in the clinic. Furthermore, except for DMSO, all of these extravasation antidotes are listed in the official FDA-approved package inserts for each vesicant agent. Thus, the inserts for vincristine and vinblastine specify hyaluronidase, for doxorubicin, glucocorticosteroids, and for mechlorethamine, sodium thiosulfate. New studies are clearly needed to clarify the role of topical DMSO with anthracyclines and mitomycin C. In addition, efforts should be made to begin clinical development of radical dimers such as DHM3 which can directly inactivate quinone-containing vesicants like doxorubicin and mitomycin C.96 Although the incidence of chemotherapy extravasation may be lessened with vascular access devices, it nonetheless, continues to comprise a serious and highly litigious area of oncology practice. This commands continued extravasation intervention studies and diligent prevention when ever possible.

Original languageEnglish (US)
Pages (from-to)41-60
Number of pages20
JournalBlood Reviews
Volume4
Issue number1
DOIs
StatePublished - 1990

Fingerprint

Antidotes
Irritants
Mitomycin
Dimethyl Sulfoxide
Drug Therapy
Doxorubicin
Mechlorethamine
Hyaluronoglucosaminidase
Anecdotes
Podophyllotoxin
Vinca Alkaloids
Product Labeling
Vascular Access Devices
Vinblastine
Alkylating Agents
Anthracyclines
Vincristine
Etoposide
Antineoplastic Agents
Cisplatin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Antidotes to vesicant chemotherapy extravasations. / Dorr, Robert T.

In: Blood Reviews, Vol. 4, No. 1, 1990, p. 41-60.

Research output: Contribution to journalArticle

@article{7f3a4f98b87241dd8095777827d0b2c5,
title = "Antidotes to vesicant chemotherapy extravasations",
abstract = "Pharmacologic Extravasation Antidotes. The foregoing sections have reviewed the experimental studies and clinical anecdotes describing potential pharmacologic antidotes to extravasations of vesicant anticancer agents. Numerous prior reviews have also suggested specific antidotes64,176-179 or very conservative, non-pharmacologic approaches.57,180 Many antidotal approaches to extravasation have not been experimentally validated and thus, few 'antidotes' share a rationale which is founded on positive experimental and clinical studies. However, using this criteria, a few active antidotes can be distilled from the literature. These are outlined in Table 6. These antidotes include isotonic ( 1 6 M) sodium thiosulfate for mechlorethamine (and optionally for cisplatin), hyaluronidase for the vinca alkaloids (and optionally for epipodophyllotoxins such as etoposide), and cooling with very topical DMSO and low dose hydrocortisone for the anthracyclines.181 For the alkylating agent mitomycin C, topical DMSO has been effective experimentally but has not yet received clinical validation, at least in published studies. Nonetheless, the severity of mitomycin C ulcerations21 and the documented safety of topical DMSO in the small series of doxorubicin extravasation patients105 argues for its use when mitomycin extravasates in the clinic. Furthermore, except for DMSO, all of these extravasation antidotes are listed in the official FDA-approved package inserts for each vesicant agent. Thus, the inserts for vincristine and vinblastine specify hyaluronidase, for doxorubicin, glucocorticosteroids, and for mechlorethamine, sodium thiosulfate. New studies are clearly needed to clarify the role of topical DMSO with anthracyclines and mitomycin C. In addition, efforts should be made to begin clinical development of radical dimers such as DHM3 which can directly inactivate quinone-containing vesicants like doxorubicin and mitomycin C.96 Although the incidence of chemotherapy extravasation may be lessened with vascular access devices, it nonetheless, continues to comprise a serious and highly litigious area of oncology practice. This commands continued extravasation intervention studies and diligent prevention when ever possible.",
author = "Dorr, {Robert T}",
year = "1990",
doi = "10.1016/0268-960X(90)90015-K",
language = "English (US)",
volume = "4",
pages = "41--60",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Antidotes to vesicant chemotherapy extravasations

AU - Dorr, Robert T

PY - 1990

Y1 - 1990

N2 - Pharmacologic Extravasation Antidotes. The foregoing sections have reviewed the experimental studies and clinical anecdotes describing potential pharmacologic antidotes to extravasations of vesicant anticancer agents. Numerous prior reviews have also suggested specific antidotes64,176-179 or very conservative, non-pharmacologic approaches.57,180 Many antidotal approaches to extravasation have not been experimentally validated and thus, few 'antidotes' share a rationale which is founded on positive experimental and clinical studies. However, using this criteria, a few active antidotes can be distilled from the literature. These are outlined in Table 6. These antidotes include isotonic ( 1 6 M) sodium thiosulfate for mechlorethamine (and optionally for cisplatin), hyaluronidase for the vinca alkaloids (and optionally for epipodophyllotoxins such as etoposide), and cooling with very topical DMSO and low dose hydrocortisone for the anthracyclines.181 For the alkylating agent mitomycin C, topical DMSO has been effective experimentally but has not yet received clinical validation, at least in published studies. Nonetheless, the severity of mitomycin C ulcerations21 and the documented safety of topical DMSO in the small series of doxorubicin extravasation patients105 argues for its use when mitomycin extravasates in the clinic. Furthermore, except for DMSO, all of these extravasation antidotes are listed in the official FDA-approved package inserts for each vesicant agent. Thus, the inserts for vincristine and vinblastine specify hyaluronidase, for doxorubicin, glucocorticosteroids, and for mechlorethamine, sodium thiosulfate. New studies are clearly needed to clarify the role of topical DMSO with anthracyclines and mitomycin C. In addition, efforts should be made to begin clinical development of radical dimers such as DHM3 which can directly inactivate quinone-containing vesicants like doxorubicin and mitomycin C.96 Although the incidence of chemotherapy extravasation may be lessened with vascular access devices, it nonetheless, continues to comprise a serious and highly litigious area of oncology practice. This commands continued extravasation intervention studies and diligent prevention when ever possible.

AB - Pharmacologic Extravasation Antidotes. The foregoing sections have reviewed the experimental studies and clinical anecdotes describing potential pharmacologic antidotes to extravasations of vesicant anticancer agents. Numerous prior reviews have also suggested specific antidotes64,176-179 or very conservative, non-pharmacologic approaches.57,180 Many antidotal approaches to extravasation have not been experimentally validated and thus, few 'antidotes' share a rationale which is founded on positive experimental and clinical studies. However, using this criteria, a few active antidotes can be distilled from the literature. These are outlined in Table 6. These antidotes include isotonic ( 1 6 M) sodium thiosulfate for mechlorethamine (and optionally for cisplatin), hyaluronidase for the vinca alkaloids (and optionally for epipodophyllotoxins such as etoposide), and cooling with very topical DMSO and low dose hydrocortisone for the anthracyclines.181 For the alkylating agent mitomycin C, topical DMSO has been effective experimentally but has not yet received clinical validation, at least in published studies. Nonetheless, the severity of mitomycin C ulcerations21 and the documented safety of topical DMSO in the small series of doxorubicin extravasation patients105 argues for its use when mitomycin extravasates in the clinic. Furthermore, except for DMSO, all of these extravasation antidotes are listed in the official FDA-approved package inserts for each vesicant agent. Thus, the inserts for vincristine and vinblastine specify hyaluronidase, for doxorubicin, glucocorticosteroids, and for mechlorethamine, sodium thiosulfate. New studies are clearly needed to clarify the role of topical DMSO with anthracyclines and mitomycin C. In addition, efforts should be made to begin clinical development of radical dimers such as DHM3 which can directly inactivate quinone-containing vesicants like doxorubicin and mitomycin C.96 Although the incidence of chemotherapy extravasation may be lessened with vascular access devices, it nonetheless, continues to comprise a serious and highly litigious area of oncology practice. This commands continued extravasation intervention studies and diligent prevention when ever possible.

UR - http://www.scopus.com/inward/record.url?scp=0025270881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025270881&partnerID=8YFLogxK

U2 - 10.1016/0268-960X(90)90015-K

DO - 10.1016/0268-960X(90)90015-K

M3 - Article

C2 - 2182147

AN - SCOPUS:0025270881

VL - 4

SP - 41

EP - 60

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 1

ER -